Revista de Saúde Pública ()

Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved

  • Josiane Moreira da Costa,
  • Cristiano Soares de Moura,
  • Cristiane Aparecida Menezes de Pádua,
  • Aline Siqueira Fogal Vegi,
  • Sérgia Maria Starling Magalhães,
  • Marina Barra Rodrigues,
  • Andréia Queiroz Ribeiro

DOI
https://doi.org/10.11606/s1518-8787.2019053000879
Journal volume & issue
Vol. 53

Abstract

Read online

ABSTRACT OBJECTIVE To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). RESULTS The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). CONCLUSIONS The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism.

Keywords